PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 x 109/l at baseline coul...
Saved in:
| Main Authors: | Simone Baldini, Luigi Rigacci, Valentina Carrai, Renato Alterini, Rajmonda Fjerza, Alberto Bosi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2012-06-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/371 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Urogenital haemorrhage secondary to Babesia gibsoni induced immune thrombocytopenia and its management with combination of romiplostim and prednisolone in a dog
by: Nadima Khan, et al.
Published: (2025-06-01) -
Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
by: Monica Carpenedo, et al.
Published: (2023-02-01) -
Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01) -
Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01) -
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)